Computational repositioning and preclinical validation of pentamidine for renal cell cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 7, 2014, Pages 1929-1941

  Zerbini, Luiz Fernando ^a,b   Bhasin, Manoj K ^b   De Vasconcellos, Jaira F ^b   Paccez, Juliano D ^a   Gu, Xuesong ^b   Kung, Andrew L ^c   Libermann, Towia A ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; PENTAMIDINE; TRANSCRIPTOME; ANTINEOPLASTIC AGENT; ANTIPROTOZOAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; BIOINFORMATICS; CANCER CELL CULTURE; CANCER GROWTH; COMPUTER PROGRAM; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; EMBRYO; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE SIGNATURE; GENETIC PARAMETERS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GENE; TUMOR XENOGRAFT; VALIDATION STUDY; ANIMAL; CARCINOMA, RENAL CELL; DRUG EFFECTS; FEMALE; MALE; NUDE MOUSE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIPROTOZOAL AGENTS; APOPTOSIS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; MICROARRAY ANALYSIS; PENTAMIDINE;

EID: 84904196560     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0750     Document Type: Article

References (43)

1. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998;159:1163-7. (Pubitemid 28172785)
2. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005;173:1853-62. (Pubitemid 40675199)
3. Dondeti VR, Wubbenhorst B, Lal P, Gordan JD, D'Andrea K, Attiyeh EF, et al. Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res 2012;72:112-21.
4. Brannon AR, Reddy A, Seiler M, Arreola A, Moore DT, Pruthi RS, et al. Molecular strati fication of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 2010;1:152-63.
5. Pantuck AJ, Belldegrun AS, Figlin RA. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med 2001;345:1711- 2.
6. Inman BA, Harrison MR, George DJ. Novel immunotherapeutic strategies in development for renal cell carcinoma. Eur Urol 2013;63:881-9.
7. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-80. (Pubitemid 40216420)
8. Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15:4220-7.
9. Park SJ, Lee JL, Park I, Park K, Ahn Y, Ahn JH, et al. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma. Chemotherapy 2012;58:468-74.
10. Le Tourneau C, Faivre S, Serova M, Raymond E. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer 2008;99:1197-203.
11. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a doubleblind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
12. Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, Haab BB, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A 2001;98:9754-9. (Pubitemid 32769376)
13. Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005;11:5730- 9.
14. Jones J, Otu HH, Grall F, Spentzos D, CanH, Aivado M, et al. Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer. J Urol 2008;179:730-6.
15. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-35. (Pubitemid 44497995)
16. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 2011;3:96ra76.
17. Maxwell PH, Wiesener MS, ChangGW,Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5. (Pubitemid 29246458)
18. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 2006;1:1458-61.
19. Alsford S, Kelly JM, Baker N, Horn D. Genetic dissection of drug resistance in trypanosomes. Parasitology 2013;140:1478-91.
20. Cordero MD, Sánchez-Alcázar JA, Bautista-Ferrufino MR, Carmona-López MI, Illanes M, Ríos MJ, et al. Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common chemotherapeutic drugs. Anticancer Drugs 2010;21:932-44.
21. Kagawa Y, Racker E. Partial resolution of the enzymes catalyzing oxidative phosphorylation. 8. Properties of a factor conferring oligomycin sensitivity on mitochondrial adenosine triphosphatase. J Biol Chem 1966;241:2461-6.
22. Cameron OG, Zubieta JK, Grunhaus L, Minoshima S. Effects of yohimbine on cerebral blood flow, symptoms, and physiological functions in humans. Psychosom Med 2000;62:549-59. (Pubitemid 30604800)
23. Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell A-G, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 2012;30:283-8.
24. Salim MTA, Aoyama H, Sugita K, Watashi K, Wakita T, Hamasaki T, et al. Potent and selective inhibition of hepatitis C virus replication by novel phenanthridinone derivatives. Biochem Biophys Res Commun 2011;415:714-9.
25. Sagdinc SG, Esme A. Theoretical and vibrational studies of 4,5-diphenyl-2-2 oxazole propionic acid (oxaprozin). Spectrochim Acta Mol Biomol Spectrosc 2010;75:1370-6.
26. Ertas M, Sagduyu A, Arac N, Uludag B, Ertekin C. Use of levodopa to relieve pain from painful symmetrical diabetic polyneuropathy. Pain 1998;75:257-9. (Pubitemid 28160136)
27. Lintermans A, Neven P, Paridaens R. Drug safety evaluation of exemestane. Expert Opin. Drug Saf 2011;10:473-87.
28. Bommi-Reddy A, Almeciga I, Sawyer J, Geisen C, Li W, Harlow E, et al. Kinase requirements in human cells. III. Altered kinase requirements in VHL -/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci U S A 2008;105:16484-9.
29. Liu Y, El-Naggar S, Darling DS, Higashi Y, Dean DC. Zeb1 links epithelial-mesenchymal transition and cellular senescence. Development 2008;135:579-88.
30. Kruck S, Eyrich C, Scharpf M, Sievert K-D, Fend F, Stenzl A, et al. Impact of an altered Wnt1/β-catenin expression on clinicopathology and prognosis in clear cell renal cell carcinoma. Int J Mol Sci 2013;14:10944-57.
31. Stratford AL, Reipas K, Hu K, Fotovati A, Brough R, Frankum J, et al. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers. Stem Cells 2012;30:1338-48.
32. Windhorst S, Fliegert R, Blechner C, Möllmann K, Hosseini Z, Günther T, et al. Inositol 1,4,5-trisphosphate 3-kinase-A is a new cell motilitypromoting protein that increases the metastatic potential of tumor cells by two functional activities. J Biol Chem 2010;285:5541-54.
33. Pathak MK, Dhawan D, Lindner DJ, Borden EC, Farver C, Yi T. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther 2002;1:1255-64.
34. Chow TYK, Alaoui-Jamali MA, Yeh C, Yuen L, Griller D. The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer. Mol Cancer Ther 2004;3:911-9. (Pubitemid 39199586)
35. Qiu G, Jiang J, Liu X. Pentamidine sensitizes chronic myelogenous leukemia K562 cells to TRAIL-induced apoptosis. Leuk Res 2012;36:1417-21.
36. Jung HJ, Suh SI, Suh MH, Baek WK, Park JW. Pentamidine reduces expression of hypoxia-inducible factor-1a in DU145 and MDA-MB-231 cancer cells. Cancer Lett 2011;303:39-46.
37. Hao W, Chang CPB, Tsao CC, Xu J. Oligomycin-induced bioenergetic adaptation in cancer cells with heterogeneous bioenergetic organization. J. Biol. Chem 2010;285:12647-54.
38. Korystov YN, Kublik LN, Kudryavtsev AA, Levitman MK, Shaposhnikova V V, Drinyaev VA, et al. Opposite effects of low oligomycin concentrations on the apoptosis of normal and tumor cells. Dokl Biol Sci 2003;392:475-7.
39. Ottonello L, Bertolotto M, Montecucco F, Bianchi G, Dallegri F. Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol 2009;157:294-306.
40. Basler JW, Piazza GA. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 2004;171:S59-62.
41. ZerbiniLF,Czibere A,WangY,CorreaRG, Otu H,JosephM,et al.Anovel pathway involving melanomadifferentiation associated gene-7/interleukin-24 mediates nonsteroidal anti-inflammatory drug-induced apoptosis and growth arrest of cancer cells. Cancer Res 2006;66:11922-31. (Pubitemid 46094205)
42. Arimochi H, Morita K. Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. Eur J Pharmacol 2006;541:17-23. (Pubitemid 43903472)
43. Mao X, Hou T, Cao B, Wang W, Li Z, Chen S, et al. The tricyclic antidepressant amitriptyline inhibits D-cyclin transactivation and induces myeloma cell apoptosis by inhibiting histone deacetylases: in vitro and in silico evidence. Mol Pharmacol 2011;79:672-80.